Industry News

Join WhatsApp Channel 

Crack GPAT — Prepare for GPAT Online

  • HLL has introduced rapid diagnostic kit under the brand name Make Sure for the quick detection of Corona virus. The test result will be available within 15 to 20 minutes. The test kit is being manufactured at HLL Manesar Factory, Gurgaon.

    The kit is one-step novel coronavirus IgM/IgG antibody detection from the human serum, plasma and/or whole blood obtained from the patient with signs and symptoms of respiratory infection.

    This device is designed to aid in the rapid differential diagnosis of COVID-19 virus infection in large population screening in our country during the current pandemic situation and this shall support in the management of control and treatment of coronavirus disease

    This kit is validated and approved by the NIV, Pune and the ICMR for use in India.

    The principle of 'MakeSure' COVID-19 IgM/IgG antibody test kit is based on antibody capture immunochromatographic assay for the simultaneous detection of IgM and IgG antibodies to COVID-19 virus in human serum, plasma and/or whole blood samples.


    HLL is planning to manufacture two lakh kits for supplying to various government units within the next 10 days. Along with that HLL has also started manufacturing of hand sanitizers under the brand name "Medigard" at their Peroorkada Factory, Thiruvananthapuram and Kanagala Factory, Belgaum.

    << Back to Pharma News

    Subscribe to PharmaTutor News Alerts by Email

  • The Council of Scientific and Industrial Research (CSIR) has adopted a five-tier strategy to fight Covid-19, which is also getting wide support from the industry to implement it. This information was provided by Dr. Shekhar C. Mande, Director General of CSIR. He was addressing an online zoom meeting with directors of 38 laboratories of CSIR to discuss the strategy related to Covid-19.

  • A lawsuit is filed against Aurobindo Pharma and Emcure Pharma by MSP Recovery Claims in Florida, USA which claims that these pharmaceutical companies hide details about presence of carcinogenic element in anti-diabetic medicines reported by law360.

    On 2nd March 2020, Valisure has tested and detected high levels of N-Nitrosodimethylamine (NDMA) in specific lots of the drug metformin, a prescription medication used to control high blood sugar in adults and adolescents with type 2 diabetes.

    Valisure’s analysis of 22 companies selling metformin and a total of 38 batches revealed 16 batches and 11 companies where NDMA levels were detected above the 96 nanograms (ng) daily acceptable intake limit.

    The Defendants knowingly and with an intent to defraud, concealed from Plaintiff and Class Members the material facts concerning their pervasive cGMP violations, and made express and implied representations to Plaintiff’s assignors and Class Members that their Metformin drugs conformed to applicable standards of quality, purity, identity and strength, were not adulterated, and were merchantable, fit for human consumption and fit for their intended purpose when, in truth and in fact, the Metformin drugs were contaminated with a probable human carcinogen.

    MSP recovery claimed in petition that, "each package of Metformin drugs sold in the United States contained a printed insert, which represented that the drug in the package had the specified properties, conformed to the specified description, and carried a guarantee of quality assurance. The Defendants knowingly or extremely recklessly made these representations with actual knowledge, or reason to know, that they were false."


    Florida class action seeking to recover USd 124 million that health insurers paid for the popular diabetes drug.

    << Back to Pharma News

    Subscribe to PharmaTutor News Alerts by Email

  • Aurobindo Pharma Limited headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, Japan PMDA, WHO, Health Canada, MCC South Africa, ANVISA Brazil.

  • In order to scale up the operations and escalate faster delivery of testing kits for the novel coronavirus (Covid-19), Pune-based molecular diagnostics company Mylab Discovery Solutions Pvt Ltd has partnered with Serum India’s CEO Adar Poonawalla and Abhijit Pawar, Chairman of APG. Funds invested will be used for scaling production of COVID-19 testing kits and expansion of molecular diagnostic solutions.

  • Dr. Reddy’s Laboratories Ltd. (along with its subsidiaries together referred to as “Dr. Reddy’s”) announced today that it is voluntarily recalling four lots (ACB902, ACB903, ACB904, ACB905) of Phytonadione Injectable Emulsion USP, 10 mg/mL, Single-Dose Ampules to the hospital level. The product is being recalled due to product complaints received due to ampules breaking and shattering, upon opening, during compounding.

  • Daiichi Sankyo Company, Limited and Kitasato Pharmaceutical Industry Co., Ltd. (hereinafter, “ Kitasato Pharmaceutical Industry”) announced the termination of their cooperative sales agreement for Influenza HA Vaccine “Daiichi Sankyo” 1 mL and Influenza HA Vaccine Syringe “Daiichi Sankyo” 0.25 mL and 0.5 mL on March 31, 2020 in Japan.

Subscribe to Industry News